Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 25pembrolizumab 20Ipilimumab 15toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Cyclophosphamide 6Blood Specimen Collection 6trametinib 5fludarabine 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5durvalumab 4binimetinib 4aldesleukin 4Interleukin-2 4Injections 4Carboplatin 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Paclitaxel 3Introns 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Melanoma × Histamine × Clear all
NCT00039234 2013-12-18

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

National Cancer Institute (NCI)

Phase 3 Unknown
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡